Clinical and pharmacological effects of treatment with a new antidepressant.
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The novel tetracyclic piperazino-azepine compound Org GB 94 in a dose of 20 mg three times daily was found to be of save markedly and significantly less side-effects and reponded equally well to patients with reactive depression and those with endogenous depression.
Abstract
The novel tetracyclic piperazino-azepine compound Org GB 94 (Tolvon, Tolvin) in a dose of 20 mg three times daily was found to be of save markedly and significantly less side-effects. Patients with reactive depression and those with endogenous depression reponded equally well to Org GB 94. No correlation was found between plasma levels of Org GB 94 and either clinical effects or side-effects. Org GB 94 did not alter the tyramine pressor response, in contrast to amitriptyline.